Enter Title


Professor Jeffrey Glenn

Professor Jeffrey Glenn is an Associate Professor of Medicine (Division of Gastroenterology & Hepatology) and Microbiology & Immunology at Stanford University School of Medicine, and the Director of the Center for Hepatitis and Liver Tissue Engineering

He also heads a research laboratory focused on studying molecular virology and the translation of that knowledge into novel antiviral strategies, as well as the development of new models with which to study hepatitis viruses and liver diseases. He is also the founder of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), and co-founder of Riboscience LLC, local biotechnology companies developing several new classes of antiviral drugs

Glenn was born in Los Angeles, and grew up in Switzerland. He received his B.A. degree in Biochemistry and French Civilization from U.C. Berkeley from where he graduated summa cum laude.  He received his M.D. and Ph.D. in Biochemistry and Biophysics from U.C.S.F..  He trained in internal medicine at Stanford University where he completed specialty training in gastroenterology, and joined the faculty in 2000

He is the principal investigator on multiple NIH grants, a member of the Viral Hepatitis Working Group for NIH Action Plan for Liver Disease Research, has served on multiple NIH Study Sections, and is the inventor on numerous patents. He is also the recipient of a Burroughs Wellcome Fund Career Award, a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, the American Gastroenterological Association Young Investigator Basic Research Award, an elected member of the American Society for Clinical Investigation, and a member of the FDA Antiviral Drugs Advisory Committee. He is also on the Executive Committee of the Stanford University ChEM-H Institute


 Dr. Peter Buggisch

Dr. Peter Buggisch is Head of the Liver Centre Hamburg at the Institute for Interdisciplinary Medicine, Asklepios HospitalStGeorg, Hamburg, Germany. He completed his Medicine degree at the Universities of Hamburg and Bonn, Germany and in Minnesota, USA before becoming a postdoctoral fellow at the Medical Clinic, University Medical Centre Hamburg-Eppendorf. Subsequently, he managed the hepatology outpatient department and the Centre for Clinical Research in Hepatology/Gastroenterology at University Medical Centre Hamburg-Eppendorf, before assuming his current position

Dr Buggisch has conducted more than 100 clinical studies focusing on HBV and HCV infection, portal hypertension, hepatocellular carcinoma, placement of portosystemic shunts and interventional endoscopy. His research also focuses on viral hepatitis and portal hypertension. A member of the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases, as well as several key national societies, Dr Buggisch is also Deputy Chair of the Foundation Board of the German Liver Foundation


Professor Adrian Ruben

Adrian Reuben is Professor of Medicine Emeritus’15 at the Medical University of South Carolina(MUSC), in Charleston SC, where, during 1993-2014, he directed the Liver Program he created

Dr. Reuben graduated in Medicine, completed Residency and Gastroenterology Fellowship in London UK, before completing a scholarship at Yale. After a Yale faculty appointment (1981-1993), he moved to MUSC to establish the Liver Service and enhance the fledgling Liver Transplant (LT) program

His continues research on Acute Liver Failure (ALF), Coagulopathy in Liver Disease, Alcohol Biomarkers, Non-Invasive Investigation of Liver Disease and Drug Hepatotoxicity. He has considerable experience in LT, portal hypertension and he edited the May 2015 issue of Clinics in Liver Disease on Hepatocellular Carcinoma. He previously pursued laboratory-based investigation of biliary lipid secretion, and hepatic fibrogenesis. He has published 100+ peer-reviewed articles, editorials, case reports, and book chapters, as well as 44 essays in the acclaimed Landmarks in Hepatology series

He has presented at national and international meetings, taught in postgraduate courses and workshops, and lectured in three continents. His participation in American Association for the Study of Liver Diseases (AASLD) committees, includes the Ethics Committee of which he was also the Chair.  He continues to lecture, perform and publish research, review manuscripts and grant applications, and write chapters and reviews. His interest in drug hepatotoxicity is exemplified by an original article in HEPATOLOGY, on Drug-Induced Liver ALF in the United States, chapters in hepatotoxicity textbooks and membership of the Hepatotoxicity Special Interest Group Steering Committee of the AASLD.  He has also first-authored a recent 16-year overview of ALF experience by the US ALF Study Group, published in April 2016 in Annals of Internal Medicine. Finally, he has very close connections with Medicine in Israel, and with Israeli Hepatology in particular. He and his late wife spent a delightful 6-month sabbatical at Hadassah in 2011/2012, and he continues to visit Israel frequently, when he lectures and teaches at major Israeli medical centers. He also has reasonable conversational Hebrew


Professor Didier Samuel

Dr. Didier Samuel, MD, PhD, is Professor of Hepatology and Gastroenterology at Université Paris-Sud, Villejuif, France. Prof Samuel is also Medical Director of the Liver Transplant Program, and Head of both the Liver and Intensive Care Units at Centre Hepatobiliaire of Universitary Hôpital Paul Brousse in Villejuif. In addition, he is Director of Inserm Research Unit 1193 at Université Paris Sud. Prof Samuel obtained his MD in 1985 and his PhD in 1994 from Université Paris-Sud, and served his internship at Hôpitaux de Paris. He is currently the Vice Dean of the Faculty of Medicine Paris Sud. His research focuses on liver transplantation, viral hepatitis, HIV, liver failure and hepatocellular carcinoma. He is a member of several scientific societies, including the Council of the International Liver Transplantation Society (ILTS, acting as President 2013-2014), the American Association for the Study of Liver Diseases (AASLD), and European Association of the Study of the Liver (EASL, he was member of the Scientific Committee 2000-2003). He served as Editor-in-Chief of Journal of Hepatology (2010-2014). Prof Samuel has published over 400 articles in peer-reviewed scientific journals and textbooks, with a H-index of 66 and has given over 300 lectures at international congresses. In 2007, he was honored with the AASLD Achievement in Liver Transplantation Award. In 2010 he was awarded in France with the Legion d'Honneur and in 2014 with the Research Prize Allianz-Fondation de France